We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Puretech Health Plc | PRTC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.00 | -2.10% | 140.00 | 16:35:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 144.40 | 139.40 | 146.00 | 140.00 | 143.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 16/12/2024 07:28 by ohisay Reminder of Liberum note last year,It is worthwhile reminding investors of the most potentially material catalysts ahead: In our opinion, the most pertinent is the Phase IIb data for LYT-100 in IPF in 2024. We believe that because LYT-100 is an analogue of the established pirfenidone, there is an above-average likelihood of success and a good chance the drug may generate a superior efficacy signal and be better tolerated at the higher dose. The results will determine the next steps,but we believe this could be a major value catalyst for PureTech and should be attractive to existing pharma players in the IPF field. We believe it is most likely that PureTech will try to sell the rights after the Phase IIb trial readout to create value for shareholders. Regardless of ownership, we expect the launch of LYT-100 in late 2026, if the trials are successful. |
Posted at 23/11/2024 10:43 by takeiteasy "PureTech Health certainly appears significantly undervalued. However, for a traditional investor looking at earnings multiples or dividend yield, valuing PureTech is tricky. As with many biotech companies, there is little revenue and substantial annual losses, and it's unclear how an investor will realise this value. In addition, the recent share tender offer left a perceived overhang, and the shares have been heavily sold off."I would like to think the firm is addressing this in two specific areas that I can see. Ensure they get a share of recurring sales income from drug developments they sell to big pharma alongside having entities within the group launced via IPOs that have a public rather than private status so analysts can impute direct market values for PRTC's retained % holding rather than rely on estimates. Given the scale of undervaluation has been shown by a number of analysts to be so great any hint now of a plan or path to addressing this MAY be enough for a rethink of the opportunity (choose words carefully here) I would like us to become more like the BG USA trust model of a public and private equity split within the portfolio :) nai etc |
Posted at 23/11/2024 10:32 by takeiteasy "We're very pleased with Seaport's $225 million Series B financing. Led by a syndicate of top-tier investors, this milestone highlights the significant progress we're making across our portfolio. The strong support from this stellar investor group not only reinforces the value generated by our unique R&D engine but also underscores our commitment to advancing transformative therapies for patients. As we look ahead to the upcoming data readout for our internal LYT-100 (deupirfenidone) program, we're excited to continue driving innovation across our portfolio with the goal of delivering impactful treatments that address significant medical needs."I think there have been 3 triggers in rapid succession: Seaport financing showing much higher valuations, 2 failed trials for major rival for Karuna treatment and suggestions of higher pharmacy income than first thought (posts 2540, 2551 and 2554) and the hope that LYT-100 will also perform well in trial results due very shortly. Given the extreme bearishness here over many years, a proverbial kick up the backside has been required to inject some life and hope back in - hopefully the above is enough to get us back to a more normalised valuation....nai etc |
Posted at 21/11/2024 09:04 by takeiteasy "PureTech, listed nine years ago, founded and sold Karuna Therapeutics for $14 billion, has demonstrated an 80% success rate in clinical trials, and has a portfolio of over 25 drug candidates, with multiple opportunities to drive more value. With a large cash balance, it is in a stronger position than ever, allowing it to advance programs further before requiring dilutive external funding. In our view, PureTech should be launching another buyback and not issuing shares at anything less than £4 or $50....Additionally, we believe that PureTech is more of a stock for generalist investors looking for diversified biotech exposure rather than specialists who tend to prefer more focused investments". - this seems a fair summary to me.I am absolutely no expert but the LYT-100 assessment seems rather conservative against other things I have read (nai etc) |
Posted at 15/11/2024 09:22 by takeiteasy Nexn pulls plug today on UK listing to move to US, I read reviews from 2 high profile UK fund managers this week who both state that they struggle to understand the Nvidia business model (i.e. won't invest despite causing major tracking error) and we witness here the sheer lack of II enthusiasm here for what is a world leading/world class business.All anecdotes on their own but continues to reinforce the impression that the UK may not be the best place to list cutting edge tech/biotech atm. So being an investor at the vanguard of exciting change can feel a lonely place. I live in hope that things may improve :) |
Posted at 01/11/2024 09:52 by colinblackbourn Should be fireworks in November .Two investor conferences coming up. |
Posted at 21/10/2024 18:59 by edwardt Some of the articles on LinkedIn really show the regard serious institutional investors have for the seaport team. |
Posted at 21/10/2024 08:00 by takeiteasy So very round numbers investors are paying c.£160m to reduce our stake in this subsidiary by about 20%....and that means they value the subsidiary at what?and what is our current MC for the overall group....please explain what is being missed here nai etc |
Posted at 06/10/2024 20:25 by takeiteasy In everyone putting so much focus on karxt progress and whether that would succeed or not, the more financially important LYT100 (arguably due to 100% ownership) seems to have been all but forgotten - let's hope management raise the profile with investors over the remainder of 2024 :) |
Posted at 11/9/2024 14:46 by marvelman The last paragraph in the header sums up what a useless job the BOD has done for investors. We are now at the price Midas reccomended buying for future growth in 2016. This has been a lifestyle company for the fat cats who pretend to run the company and a disaster for the rest of us. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
